CollPlant Biotechnologies (CLGN) Return on Capital Employed (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Return on Capital Employed came in at 52.5% in Q4 2025, down 5593.0% YoY from 0.96% in Q4 2024, and down 15.85% on a QoQ basis from 45.32% in Q3 2025.
CollPlant Biotechnologies (CLGN) Return on Capital Employed (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Return on Capital Employed data on file, last reported at 52.5% in Q4 2025.
- Quarterly Return on Capital Employed fell 5593.0% year-over-year to 52.5% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 52.5% (down 5593.0% YoY) and the FY2025 annual result came in at 95.09%, down 2152.0% from the prior year.
- Return on Capital Employed fell to 52.5% in Q4 2025, from 45.32% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 35549.32% in Q1 2021 to a low of 52.5% in Q4 2025.
- A 5-year average of 2128.58% and a median of 5.99% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed jumped 3559592 bps — and 2022, when it tumbled 3556240 bps.
- Tracing CLGN's Return on Capital Employed over 5 years: stood at 0.13% in 2021, then sank by 20257 bps to 26.52% in 2022, then jumped by 87 bps to 3.43% in 2023, then surged by 200 bps to 3.42% in 2024, then sank by 1633 bps to 52.5% in 2025.
- The last three Return on Capital Employed figures came in at 52.5% (Q4 2025), 45.32% (Q3 2025), and 3.42% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -52.50% |
| Sep 30, 2025 | -45.32% |
| Dec 31, 2024 | 3.42% |
| Sep 30, 2024 | -8.56% |
| Jun 30, 2024 | -9.30% |
| Mar 31, 2024 | 2.46% |
| Dec 31, 2023 | -3.43% |
| Sep 30, 2023 | -0.45% |
| Jun 30, 2023 | 0.14% |
| Mar 31, 2023 | -28.99% |
| Dec 31, 2022 | -26.52% |
| Sep 30, 2022 | -21.64% |
| Jun 30, 2022 | -16.55% |
| Mar 31, 2022 | -13.08% |
| Dec 31, 2021 | 0.13% |
| Sep 30, 2021 | -3.33% |
| Jun 30, 2021 | 2,988.65% |
| Mar 31, 2021 | 35,549.32% |
| Dec 31, 2020 | 8,607.37% |
| Sep 30, 2020 | 8,184.71% |